These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 33283236)

  • 21. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
    Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
    Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
    Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
    Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
    Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
    BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study.
    Ohnuma H; Sato Y; Hirakawa M; Kikuchi S; Miyanishi K; Sagawa T; Takahashi Y; Nobuoka T; Okamoto K; Miyamoto H; Takemasa I; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):539-548. PubMed ID: 29383482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
    Nakata B; Tsuji A; Mitachi Y; Taenaka N; Kamano T; Oikawa K; Onoda N; Kambe M; Takahashi M; Shirasaka T; Morita S; Sakamoto J; Tanaka Y; Saji S; Hirakawa K
    Oncology; 2010; 79(5-6):337-42. PubMed ID: 21430401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].
    Kemmochi T; Egawa T; Mihara Y; Irino T; Ito Y; Nagashima A; Makino H; Yamamuro W
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2351-3. PubMed ID: 22202379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
    Nishiwaki H; Yamada T; Tachi K; Iwasaki H; Hori Y; Umemura S; Yamakawa Y; Kurimoto T; Ban T; Fujiwara K; Hayashi K; Nemoto A; Shiroko J; Orito E
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1663-6. PubMed ID: 19838024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study.
    Kunisaki C; Ono HA; Hasegawa S; Oshima T; Fujii S; Tokuhisa M; Izumisawa Y; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    J Chemother; 2012 Dec; 24(6):364-8. PubMed ID: 23174102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction.
    Hosoda K; Azuma M; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Tanabe S; Koizumi W; Yamashita K; Hiki N
    Int J Clin Oncol; 2020 Jun; 25(6):1090-1097. PubMed ID: 32124094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical trials of neo-adjuvant chemotherapy for advanced gastric cancer with peritoneal dissemination].
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamazaki M; Nishida T; Doki Y
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):1996-8. PubMed ID: 19106502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Makino H; Takagawa R; Kimura J; Ono H; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):281-5. PubMed ID: 24253176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and S-1 for Resectable Advanced Esophageal Cancer.
    Hayata K; Ojima T; Nakamori M; Nakamura M; Katsuda M; Kitadani J; Takeuchi A; Tabata H; Maruoka S; Yamaue H
    Anticancer Res; 2018 Sep; 38(9):5267-5273. PubMed ID: 30194177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].
    Imai H; Obana N; Iwabuchi T; Satou Y; Ooyauchi M; Igarashi T; Matsumoto H; Sakamoto K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1185-8. PubMed ID: 18633259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical experience of chemotherapy with S-1/CDDP for highly-advanced gastric cancer].
    Uchima Y; Kosaka K; Kimura K; Okita Y; Sim JK; Aomatsu N; Hirata K; Lee WH; Lee T; Nishii T; Tei S; Takeuchi K
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1287-90. PubMed ID: 20647711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.